請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46464完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 陳義雄 | |
| dc.contributor.author | Jei-Ming Peng | en |
| dc.contributor.author | 彭瑞銘 | zh_TW |
| dc.date.accessioned | 2021-06-15T05:10:24Z | - |
| dc.date.available | 2011-08-22 | |
| dc.date.copyright | 2011-08-22 | |
| dc.date.issued | 2011 | |
| dc.date.submitted | 2011-08-18 | |
| dc.identifier.citation | Acharya, R., Fry, E., Stuart, D., Fox, G., Rowlands, D., and Brown, F. (1989) Nature 337(6209), 709-716
Al-Khouri AM, Ma Y, Togo SH, Williams S, Mustelin T (2005). Cooperative phosphorylation of the tumor suppressor phosphatase and tensin homologue (PTEN) by casein kinases and glycogen synthase kinase 3beta. J Biol Chem 280: 35195-35202. Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW et al. (1996). Human ICE/CED-3 protease nomenclature. Cell 87:171. Andre E, Becker-Andre M (1993). Expression of an N-termically truncated form of human focal adhesion kinase in brain. Biochemical and biophysical research communications 190:140-7. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. (2006). Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354: 34-43. Auersperg N, Wong AS, Choi KC, Kang SK, Leung PC (2001). Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr Rev 22: 255-288. Bacac M, Stamenkovic I (2008). Metastatic cancer cell. Annual Review of Pathology. 3:221-47. Baudhuin, L. M., Jiang, Y., Zaslavsky, A., Ishii, I., Chun, J., and Xu, Y. (2004) Faseb J 18(2), 341-343 Bayry, J., Prabhudas, K., Gopalakrishna, S., Patil, P. K., Ramakrishna, C., Misra, L. D., and Suryanarayana, V. V. (1999) Microbiol Immunol 43(8), 765-771 Belsham, G. J. (1993) Prog Biophys Mol Biol 60(3), 241-260 Belham, C., Wu, S., and Avruch, J. (1999) Curr Biol 9(3), R93-96 Benetti, L., Munger, J., and Roizman, B. (2003) J Virol 77(11), 6567-6573 Brognard, J., Clark, A. S., Ni, Y., and Dennis, P. A. (2001) Cancer Res 61(10), 3986-3997 Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., and Greenberg, M. E. (1999) Cell 96(6), 857-868 Buckley, C. D., Pilling, D., Henriquez, N. V., Parsonage, G., Threlfall, K., Scheel-Toellner, D., Simmons, D. L., Akbar, A. N., Lord, J. M., and Salmon, M. (1999) Nature 397(6719), 534-539 Buczek-Thomas JA, Chen N, Hasan T (1998). Integrin-mediated adhesion and signalling in ovarian cancer cells. Cell Signal. 10:55-63. Calderwood DA (2004). Talin controls integrin activation. Biochem. Soc. Trans. 32:434-7. Cannistra SA (2004). Cancer of the ovary. N Engl J Med 351: 2519-2529. Cardone, M. H., Roy, N., Stennicke, H. R., Salvesen, G. S., Franke, T. F., Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282(5392), 1318-1321 Chetty C, Lakka SS, Bhoopathi P, Rao JS (2010). MMP-2 alters VEGF expression via alphaVbeta3 integrin-mediated PI3K/AKT signaling in A549 lung cancer cells. Int J Cancer 127: 1081-1095. Chiang AC, Massague J (2008) Molecular basis of metastasis. The New England J. of Medicine. 359:2814-23. Chou TC (2006). Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies. Pharmacol Rev 58: 621-681. Chu EC, Tarnawski AS (2004). PTEN regulatory functions in tumor suppression and cell biology. Med. Sci. Monit. 10:RA235-41. Cominetti MR, Terruggi CH, Ramos OH, Fox JW, Mariano-Oliveira A, De Freitas MS, et al. (2004). Alternagin-C, a disintegrin-like protein, induces vascular endothelial cell growth factor (VEGF) expression and endothelial cell proliferation in vitro. J Biol Chem 279: 18247-18255. Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A. (1995) Nature 378(6559), 785-789 Datta, S. R., Brunet, A., and Greenberg, M. E. (1999) Genes Dev 13(22), 2905-2927 Dedhar S (1999). Integrins and signal transduction. Curr Opin Hematol 6: 37-43. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S (1998). Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci U S A 95: 11211-11216. Du, Z., Regier, D. A., and Desrosiers, R. C. (1995) Biotechniques 18(3), 376-378 Baxt, B., Morgan, D. O., Robertson, B. H., and Timpone, C. A. (1984) J Virol 51(2), 298-305 Fornari FA, Randolph JK, Yalowich JC, Ritke MK, Gewirtz DA (1994). Interference by doxorubicin with DNA unwinding in MCF-7 breast tumor cells. Mol. PHarmacol. 45:649-56. Franke, T. F., Kaplan, D. R., and Cantley, L. C. (1997) Cell 88(4), 435-437 Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., Vessella, R. L., and Neubauer, B. L. (2000) J Biol Chem 275(32), 24500-24505 Guan JL, Shalloway D (1992). Regulation of focal adhesion-associated protein tyrosine kinase by both cellular adhesion and oncogenic transformation. Nature 258:690-2. Harper E, Bloch K, Gross J (1971). The zymogen of tadpole collagenase. Biochemistry 10:3035-41. Hermann P, Armant M, Brown E, Rubio M, Ishihara H, Ulrich D et al. (1999). The vitronectin receptor and its associated CD47 molucule mediates proinflammatory cytokine synthesis in human monocytes by interaction with soluble CD23. J. Cell Biol. 144:767-75. Ho MY, Leu SJ, Sun GH, Tao MH, Tang SJ, Sun KH (2009). IL-27 directly restrains lung tumorigenicity by suppressing cyclooxygenase-2-mediated activities. J Immunol 183: 6217-6226. Huang CY, Liang CM, Chu CL, Liang SM (2009). Albumin fibrillization induces apoptosis via integrin/FAK/Akt pathway. BMC Biotechnol 9: 1-12. Huang TF, Holt JC, Kirby EP, Niewiarowski S (1989). Trigramin: primary structure and its inhibition of von Willebrand factor binding to glycoprotein IIb/IIIa complex on human platelets. Biochemistry 28: 661-666. Hutchinson, J., Jin, J., Cardiff, R. D., Woodgett, J. R., and Muller, W. J. (2001) Mol Cell Biol 21(6), 2203-2212 Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009). Cancer statistics, 2009. CA Cancer J Clin 59: 225-249. Johnsen M, Lund LR, Romer J, Almholt K, Dano K (1998). Cancer invasion and tissue remodeling: common themes in proteolytic matrix degradation. Curr Opin Cell Biol 10: 667-671. Jackson, T., Blakemore, W., Newman, J. W., Knowles, N. J., Mould, A. P., Humphries, M. J., and King, A. M. (2000) J Gen Virol 81(Pt 5), 1383-1391 Jackson, T., Sheppard, D., Denyer, M., Blakemore, W., and King, A. M. (2000) J Virol 74(11), 4949-4956 Jackson, T., Mould, A. P., Sheppard, D., and King, A. M. (2002) J Virol 76(3), 935-941 Kenjiro S, Anirban K, Mitra A, Reza R, Vinay B, Emily O et al. (2008). Loss of E-cadherin promotes ovarian cancer metastasis via α5-integrin, which is a therapeutic target. 68:2329. Kiaris, H., and Schally, A. V. (1999) Proc Soc Exp Biol Med 221(2), 87-88 King, W. G., Mattaliano, M. D., Chan, T. O., Tsichlis, P. N., and Brugge, J. S. (1997) Mol Cell Biol 17(8), 4406-4418 Klauber N, Parangi S, Flynn E, Hamel E, D'Amato RJ (1997). Inhibition of angiogenesis and breast cancer in mice by the microtubule inhibitors 2-methoxyestradiol and taxol. Cancer Res 57: 81-86. Klein CA (2008). Cancer. The metastasis cascade. Science 321:1785-7. Kopfstein L, Christofori G (2006). Metastasis: cell-autonomous mechanisms versus contributions by the tumor microenvironment. Cell Mol Life Sci 63: 449-468. Kosary, Carol L (2007). Chapter 16: Cancers of the Ovary. Bethesda, MD: National Cancer Insitute. pp. 133-44. Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS (2005). Robbins and Cotran pathologic basis of disease (7th ed.). Philadelphia: Elsevier Saunders. Lau DH, Xue L, Young LJ, Burke PA, Cheung AT (1999). Paclitaxel (Taxol): an inhibitor of angiogenesis in a highly vascularized transgenic breast cancer. Cancer Biother Radiopharm 14: 31-36. Lee CD, Yan YP, Liang SM, Wang TF (2009). Production of FMDV Virus-like particle by a SUMO fusion protein approach in Escherichia coli. J Biomed Sci 16:69-75. Lee, Y. I., Kang-Park, S., and Do, S. I. (2001) J Biol Chem 276(20), 16969-16977 Leevers SJ, Vanhaesebroeck B, Waterfield MD (1999). Signaling through phosphoinositide 3-kinases: the lipids take centre stage. Current Opinion in Cell Biology 11:219-25. Li, M. O., Sarkisian, M. R., Mehal, W. Z., Rakic, P., and Flavell, R. A. (2003) Science 302(5650), 1560-1563 Loberg, R. D., Vesely, E., and Brosius, F. C., 3rd. (2002) J Biol Chem 277(44), 41667-41673 Logan, D., Abu-Ghazaleh, R., Blakemore, W., Curry, S., Jackson, T., King, A., Lea, S., Lewis, R., Newman, J., Parry, N., and et al. (1993) Nature 362(6420), 566-568 Lowe J, Li H, Downing KH, Nogales E (2001). Refined structure of αβ-tubulin at 3,5 A resolution. J. Mol. Biol. 313:1045-57. Lucie S, Elisabeth G, Stephanie F, Guy S, Amandine H, Corinne AR, et al. (2009). Clustering and internalization of integrin αvβ3 with a tetrameric RGD-synthetic peptide. Mol Ther 17: 837-843. Luo, H. R., Hattori, H., Hossain, M. A., Hester, L., Huang, Y., Lee-Kwon, W., Donowitz, M., Nagata, E., and Snyder, S. H. (2003) Proc Natl Acad Sci U S A 100(20), 11712-11717 Mano MS, Rosa DD, Azambuja E, Ismael G, Braga S, D'Hondt V, et al. (2007). Current management of ovarian carcinosarcoma. Int J Gynecol Cancer 17: 316-324. Marte, B. M., and Downward, J. (1997) Trends Biochem Sci 22(9), 355-358 Martinez, A., Alonso, M., Castro, A., Perez, C., and Moreno, F. J. (2002) J Med Chem 45(6), 1292-1299 Martinez-Salas E, Saiz M, Sobrino F (2008). Foot-and-Mouth disease virus. Animal Viruses: Molecular Biology. Caister Academic Press. pp. 1-38. Mateu, M. G., Valero, M. L., Andreu, D., and Domingo, E. (1996) J Biol Chem 271(22), 12814-12819 McLane MA, Marcinkiewicz C, Vijay-Kumar S, Wierzbicka-Patynowski I, Niewiarowski S (1998). Viper venom disintegrins and related molecules. Proc Soc Exp Biol Med 219: 109-119. Monparler RL, Karon M, Siegel SE, Avila F (1976). Effect of adriamycin on DNA, RNA, and protein synthesis in cell-free systems and intact cells. Cancer Res. 36:2891-5. Murphy G, Ward R, Hembry RM, Reynolds JJ, Kuhn K, Tryggvason K (1989). Characterization of gelatinase from pig polymorphonuclear leucocytes. A metalloproteinase resembling tumour type IV collagenase. Biochem J 258: 463-472. Niedzwiecki A, Roomi MW, Kalinovsky T, Rath M (2010). Micronutrient synergy--a new tool in effective control of metastasis and other key mechanisms of cancer. Cancer Metastasis Rev 29: 529-542. Nishida, K., Misumi, O., Yagisawa, F., Kuroiwa, H., Nagata, T., and Kuroiwa, T. (2004) J Histochem Cytochem 52(7), 843-849 Oliva IB, Coelho RM, Barcellos GG, Saldanha-Gama R, Wermelinger LS, Marcinkiewicz C, et al. (2007). Effect of RGD-disintegrins on melanoma cell growth and metastasis: involvement of the actin cytoskeleton, FAK and c-Fos. Toxicon 50: 1053-1063. Ozcelik B, Turkyilmaz C, Ozgun MT et al. (2010). Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormaone agonist. Fertil. Steril. 93:1609-14. Park JK, Park SH, So K, Bae IH, Yoo YD, Um HD (2010). ICAM-3 enhances the migratory and invasive potential of human non-small cell lung cancer cells by inducing MMP-2 and MMP-9 via Akt and CREB. Int J Oncol 36: 181-192. Patil, P. K., Suryanarayana, V., Bist, P., Bayry, J., and Natarajan, C. (2002) Vaccine 20(7-8), 1163-1168 Pei D, Kang T, Qi H (2000). Cysteine array matrix metalloproteinase (CA-MMP)/MMP-23 is a type II transmembrane matrix metalloproteinase regulated by a single cleavage for both secretion and activation. J. Biol. Chem. 275:33988-97. Peng JM, Liang SM, Liang CM (2004). VP1 of foot-and-mouth disease virus induces apoptosis via the Akt signaling pathway. J Biol Chem 279: 52168-52174. Pierschbacher, M. D., and Ruoslahti, E. (1984) Nature 309(5963), 30-33 Plyte SE, Hughes K, Nikolakaki E, Pulverer BJ, Woodgett JR (1992). Glycogen synthase kinase-3: functions in oncogenesis and development. Biochim. Biophys. Acta 1114:147-62. Pytela, R., Pierschbacher, M. D., and Ruoslahti, E. (1985) Cell 40(1), 191-198 Hynes, R. O. (1992) Cell 69(1), 11-25 Remacle AG, Rozanov DV, Fugere M, Day R, Strongin AY (2006). Furin regulates the intracellular activation and the uptake rate of cell surface-associated MT1-MMP. Oncogene. 25:5648-55. Roivainen, M., Hyypia, T., Piirainen, L., Kalkkinen, N., Stanway, G., and Hovi, T. (1991) J Virol 65(9), 4735-4740 Rowinsky EK, Donehower RC (1995). Paclitaxel (taxol). N Engl J Med 332: 1004-1014. Roy, H. K., Olusola, B. F., Clemens, D. L., Karolski, W. J., Ratashak, A., Lynch, H. T., and Smyrk, T. C. (2002) Carcinogenesis 23(1), 201-205 Ruoslahti, E. (2003) Matrix Biol 22(6), 459-465 Sa-Carvalho, D., Rieder, E., Baxt, B., Rodarte, R., Tanuri, A., and Mason, P. W. (1997) J Virol 71(7), 5115-5123 Schneller, M., Vuori, K., and Ruoslahti, E. (1997) Embo J 16(18), 5600-5607 Hemmings, B. A. (1997) Science 275(5300), 628-630 Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. (2007). EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem 282: 28609-28618. Shaw TJ, Senterman MK, Dawson K, Crane CA, Vanderhyden BC (2004). Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther 10: 1032-1042. Shieh, J. J., Liang, C. M., Chen, C. Y., Lee, F., Jong, M. H., Lai, S. S., and Liang, S. M. (2001) Vaccine 19(28-29), 4002-4010 Slee, E. A., Harte, M. T., Kluck, R. M., Wolf, B. B., Casiano, C. A., Newmeyer, D. D., Wang, H. G., Reed, J. C., Nicholson, D. W., Alnemri, E. S., Green, D. R., and Martin, S. J. (1999) J Cell Biol 144(2), 281-292 Songyang Z, Shoelson SE, Chaudhuri M et al., (1993). SH2 domains recognize specific phosphopeptide sequences. Cell 72: 767-778. Spankuch B, Strebhardt K (2008). Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment. Curr Pharm Des 14: 1098-1112. Srinivasula, S. M., Fernandes-Alnemri, T., Zangrilli, J., Robertson, N., Armstrong, R. C., Wang, L., Trapani, J. A., Tomaselli, K. J., Litwack, G., and Alnemri, E. S. (1996) J Biol Chem 271(43), 27099-27106 Stanbridge, E., Frisch, S., and Reed, J. C. (1998) Science 282(5392), 1318-1321 Stanway, G., Kalkkinen, N., Roivainen, M., Ghazi, F., Khan, M., Smyth, M., Meurman, O., and Hyypia, T. (1994) J Virol 68(12), 8232-8238 Stearns ME, Wang M (1992). Taxol blocks processes essential for prostate tumor cell (PC-3 ML) invasion and metastases. Cancer Res 52: 3776-3781. Stetler-Stevenson WG (1999). Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 103: 1237-1241. Stoeltzing, O., Liu, W., Reinmuth, N., Fan, F., Parry, G. C., Parikh, A. A., McCarty, M. F., Bucana, C. D., Mazar, A. P., and Ellis, L. M. (2003) Int J Cancer 104(4), 496-503 Stordl B, Davey M (2007). Understanding cisplatin resistance using cellular models. IUBMB Life 59:696-9. Stordal B, Pavlakis N, Davey R (2007). A systematic review of platinum and tzeane resistance from bench to clinic: an inverse relationship. Cancer Treat. Rev 33:688-703. Strobel T, Cannistra SA (1999). Beta1-integrins partyly mediate binding of ovarian cancer cells to peritoneal mesothelium in vitro. 73:362-7. Surovoi, A., Ivanov, V. T., Chepurkin, A. V., Ivaniushchenkov, V. N., and Driagalin, N. N. (1988) Bioorg Khim 14(7), 965-968 Swenson S, Costa F, Ernst W, Fujii G, Markland FS (2005). Contortrostatin, a snake venom disintegrin with anti-angiogenic and anti-tumor activity. Pathophysiol Haemost Thromb 34: 169-176. Trexler M, Briknarova K, Gehrmann M, Llinas M, Patthy L (2003). Peptide ligands for the fibronectin type II modules of matrix metalloproteinase 2 (MMP-2). J. Biol. Chem 278:12241-6. Tsuruo, T., Naito, M., Tomida, A., Fujita, N., Mashima, T., Sakamoto, H., and Haga, N. (2003) Cancer Sci 94(1), 15-21 Toker, A. (2000) Mol Pharmacol 57(4), 652-658 Van Lint P, Libert C (2007). Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. J. Leukoc. Biol. 82:1375-81. Vlahos, C. J., Matter, W. F., Hui, K. Y., and Brown, R. F. (1994) J Biol Chem 269(7), 5241-5248 Vuori, K. (1998) J Membr Biol 165(3), 191-199 Wang, J. H., Liang, C. M., Peng, J. M., Shieh, J. J., Jong, M. H., Lin, Y. L., Sieber, M., and Liang, S. M. (2003) Vaccine 21(25-26), 3721-3729 Weidner N, Semple JP, Welch WR, Folkman J (1991). Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. Engl. J. Med. 324:1-8. Wickham, T. J., Mathias, P., Cheresh, D. A., and Nemerow, G. R. (1993) Cell 73(2), 309-319 Wilson KP, Black JA, Thomson JA et al. (1994). Structure and mechanism of interleukin-1 beta converting enzyme. Nature 370:270-5. Woessner JF, Jr. (1991). Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5: 2145-2154. Woolhouse, M., Chase-Topping, M., Haydon, D., Friar, J., Matthews, L., Hughes, G., Shaw, D., Wilesmith, J., Donaldson, A., Cornell, S., Keeling, M., and Grenfell, B. (2001) Nature 411(6835), 258-259 Wu, W., Lee, W. L., Wu, Y. Y., Chen, D., Liu, T. J., Jang, A., Sharma, P. M., and Wang, P. H. (2000) J Biol Chem 275(51), 40113-40119 Wulfkuhle JM, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA et al. (2003) Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 3:2084-90. Yoakim M, Hou W, Songyang Z, Liu Y, Cantley L, Schaffhausen B. (1994). Genetic analysis of a phosphatidylinositol 3-kinase SH2 domain reveals determinants of specificity. Mol Cell Biol 14:5929-5938. Yu D, Wolf JK, Scanlon M, Price JE, Hung MC (1993). Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898. Zhang, H. M., Yuan, J., Cheung, P., Luo, H., Yanagawa, B., Chau, D., Stephan-Tozy, N., Wong, B. W., Zhang, J., Wilson, J. E., McManus, B. M., and Yang, D. (2003) J Biol Chem 278(35), 33011-33019 Zhang Z, Song T, Jin Y, Pan J, Zhang L, Wang L, et al. (2009). Epidermal growth factor receptor regulates MT1-MMP and MMP-2 synthesis in SiHa cells via both PI3-K/AKT and MAPK/ERK pathways. Int J Gynecol Cancer 19: 998-1003. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/46464 | - |
| dc.description.abstract | 口蹄疫病毒(FMDV)是經由其表面鞘蛋白質(VP1)上具有特殊的精胺酸，甘胺酸和天門冬胺酸等胺基酸來結合到細胞表面的integrin結合子。目前尚未清楚的是在此鞘蛋白質(VP1)結合到細胞表面之後，會刺激細胞有什麼樣的細胞反應。首先，我們成功的利用重組DNA的方式，純化出可水溶性的口蹄疫病毒表面鞘蛋白質(rVP1)，並發現此重組鞘蛋白質可以結合到倉鼠腎細胞表面的integrin結合子，並且引發細胞自體計畫性死亡反應。除此之外，我們並發現將重組蛋白質rVP1處理到倉鼠腎細胞，會引起Akt蛋白質的去活化，並引發下游細胞自體計畫性死亡反應，包括GSK-3B蛋白質的去磷酸化和procaspase -3, -7和-9等蛋白質的活化。此外，進一步的研究發現經重組蛋白質rVP1處理過後會引起癌細胞的自體計畫性死亡，包含: 人類乳癌細胞株(MCF-7，T-47D，MDA-MB-231)，人類前列腺癌細胞株(22Rv1，PC-3)和人類卵巢癌細胞株(SKOV3，OVCAR-3，TOV-21G)。
目前對於具轉移情況的卵巢癌病患其治療成果仍然不佳，更進一步的研發能抑制癌細胞轉移能力的藥物是迫不及待的。我們的研究發現重組蛋白質rVP1在卵巢癌細胞作用的機制，其發現其不但具有抑制卵巢癌細胞生長的效果更能在小鼠體內成功抑制癌細胞的轉移。我們的結果發現重組蛋白質rVP1會在卵巢癌細胞引發自體計畫性死亡和減少其轉移能力。這個機制是經由活化細胞內的PTEN蛋白質和GSK-3B蛋白質，並抑制FAK，Akt和MMP-2蛋白質的活性。利用抗integrin結合子的抗體或是大量表現可持續具有活性的Akt可以大幅減低重組蛋白質rVP1的作用。並經由在小鼠原位引發卵巢癌和腹腔注射卵巢癌細胞的方法，發現重組蛋白質rVP1可以在體內抑制卵巢癌細胞的生長和轉移。經由在冷光顯像系統和免疫染色方法分析在小鼠體內的癌細胞其Akt和GSK-3B蛋白質的活性皆受到重組蛋白質rVP1調控。這些結果呈現出重組蛋白質rVP1經由負調控Akt蛋白質下游反應和減低MMP-2蛋白質活性後，具有在小鼠體內抑制卵巢癌細胞的生長和轉移的能力。 | zh_TW |
| dc.description.abstract | VP1, a capsid protein of Foot-and-mouth disease virus (FMDV), binds to cellular integrins through an arginine-glycine-aspartic acid motif. It is unclear, however, what kind of cellular event(s) is triggered after the binding of VP1 to the cells. First of all, we found that aqueous soluble recombinant DNA derived VP1 (rVP1) of FMDV induced apoptosis in BHK-21 cells after binding to integrins. In addition, treatment of BHK-21 cells with rVP1 resulted in deactivating Akt, and enhancing several pro-apoptotic responses, such as dephosphorylation of GSK-3β and cleavage of procaspase -3, -7 and -9. We also illustrated that the rVP1 treatment caused apoptosis of cancer cells including human breast carcinoma (MCF-7, T-47D, MDA-MB-231), human prostate cancer (22Rv1, PC-3) and human ovarian cancer (SKOV3, OVCAR-3, TOV-21G).
As prognosis for patients with metastatic ovarian cancer is generally poor, advances in treatments are needed. We have studied the effect of rVP1 on ovarian tumor growth and metastasis in vivo. We showed that rVP1 promoted the apoptosis of human ovarian cancer cells and decreased the cell invasion. This effect of rVP1 was accompanied by the activation of PTEN and GSK-3β as well as downregulation of FAK, Akt and MMP-2. Anti-integrin antibodies or overexpression of constitutively active Akt reversed the cellular effects of rVP1. Orthotopic and intraperitoneal xenograft mouse models demonstrated that rVP1 attenuated survival and metastasis of human ovarian cancer SKOV3 cell line in vivo through selective regulation of Akt and GSK-3β activity as revealed by bioluminescence imaging of mice and immunohistochemical analysis. These results indicate that negative regulation of Akt signaling and MMP-2 by rVP1 may have the potential to suppress ovarian tumor growth and metastasis in vivo. | en |
| dc.description.provenance | Made available in DSpace on 2021-06-15T05:10:24Z (GMT). No. of bitstreams: 1 ntu-100-D93b46008-1.pdf: 37296704 bytes, checksum: 1498007464b8e4f90004da93cc3da8e1 (MD5) Previous issue date: 2011 | en |
| dc.description.tableofcontents | Table of Contents i
List of Figures iv Abbreviations ix Abstract xi 中文摘要 xiii Introduction 1 Materials and Methods 26 1. Materials 26 2. Site-directed mutagenesis 27 3. Expression and purification of rVP1 28 4. Cell lines and Treatments 28 5. DNA Fragmentation Assay by eletrophoresis analysis 30 6. DAPI stain for Cell Survival and Apoptosis 31 7. Cell Transfection and Plasmid Expression 31 8. Indirect Immunofluorescence 32 9. Cell viability assay 32 10. Internalization of rVP1 on SKOV3 cells 33 11. Caspase activity assay 34 12. DNA fragmentation assay 34 13. Matrigel invasion assay 35 14. Gelatin zymographic analysis 36 15. Isolation of intraperitoneal cells 36 16. Preparation of pCMV-GFP/leuciferase-lentivirus and establishment of a stable SKOV3-GL cell line 37 17. Detection of luciferase activity in vivo by bioluminescence imaging 38 18. Immunohistochemistry 39 19. Orthotopic xenograft mouse model of ovarian cancer 40 20. Intraperitoneal xenograft mouse model of ovarian cancer 41 21. Statistical analysis 42 Results 43 1. rVP1 induces apoptosis 43 2. rVP1 is more potent than cRGD and p29 in inhibitio of cell viability 44 3. rVP1 induces apoptosis by binding to integrin 44 4. rVP1 treatment deactivates Akt 46 5. rVP1 activates cleavage of procaspases 47 6. rVP1 binds to the surface of cancer cell 48 7. rVP1 induces DNA fragmentation in cancer cell 48 8. rVP1 induces cancer apoptosis disregarding the absence of caspase-3 and S1P3. 49 9. MCD can reverse rVP1 induced DNA fragmentation in cancer cell 50 10. rVP1 induces apoptosis and suppresses invasion of ovarian cancer cells in vitro 51 11. rVP1 inhibits survival of SKOV3 cells via dephosphorylation of Akt, GSK-3β and phosphorylation of PTEN 52 12. rVP1 reduces invasive capacity of SKOV3 cells via integrin and Akt/MMP-2 54 13. rVP1 reduces tumor growth and metastasis of SKOV3 cells in an orthotopic xenograft mouse model 55 14. rVP1 reduces advanced stage ovarian tumor and metastasis in an intraperitoneal xenograft mouse model 57 15. rVP1 reduces early stage ovarian tumor and metastasis in an intraperitoneal xenograft mouse model 59 16. rVP1 can not reduces SKOV3Akt-DA tumor and metastasis in an orthotopic xenograft mouse model 60 17. rVP1 suppresses invasive capacity of peritoneal adapted SKOV3 cells via integrin and Akt/MMP-2 61 18. rVP1 shows a synergistic effect with doxorubicin and cisplatin in cancer cells 62 19. MCD and anti-α5β1 antibody can not reverse doxorubicin and cisplatin induced cell death 63 20. rVP1 binds and inhibits the activity of topoisomerase II 64 21. Both paclitaxel and rVP1 reduces SKOV3 tumor and metastasis in an orthotopic xenograft mouse model 64 Discussion 66-75 Figure 76-153 Table 154-155 Reference 156-166 Appendix 167-171 | |
| dc.language.iso | zh-TW | |
| dc.subject | 自發性死忙 | zh_TW |
| dc.subject | 卵巢癌 | zh_TW |
| dc.subject | 結合子 | zh_TW |
| dc.subject | 轉移 | zh_TW |
| dc.subject | 化療藥物 | zh_TW |
| dc.subject | integrin | en |
| dc.subject | ovarian cancer | en |
| dc.subject | chemotherapeutic agent | en |
| dc.subject | apoptosis | en |
| dc.subject | metastasis | en |
| dc.title | 重組病毒鞘蛋白質rVP1抑制癌細胞生存及轉移機制研究 | zh_TW |
| dc.title | Study of the Cancer Suppressive Effect of a Recombinant Viral Protein in Cancer Cells | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 99-2 | |
| dc.description.degree | 博士 | |
| dc.contributor.coadvisor | 梁啟銘 | |
| dc.contributor.oralexamcommittee | 楊淑美,陳鈴津,李明亭,蕭宏昇 | |
| dc.subject.keyword | 化療藥物,自發性死忙,轉移,結合子,卵巢癌, | zh_TW |
| dc.subject.keyword | chemotherapeutic agent,apoptosis,metastasis,integrin,ovarian cancer, | en |
| dc.relation.page | 171 | |
| dc.rights.note | 有償授權 | |
| dc.date.accepted | 2011-08-18 | |
| dc.contributor.author-college | 生命科學院 | zh_TW |
| dc.contributor.author-dept | 生化科學研究所 | zh_TW |
| 顯示於系所單位： | 生化科學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| ntu-100-1.pdf 未授權公開取用 | 36.42 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。